DCLK1 and neoplasm: Immunohistochemistry of primary tumor sections for the stem cell marker (DCLK1) demonstrated that tumors from mice treated with gemcitabine alone, or in dual combinations with either AMG102 or compound-A exhibited higher expression of DCLK1 (Figure 5).